Defining prognostic parameters of well-differentiated gastric neuroendocrine tumors based on metastatic potential: a two-center experience

被引:5
|
作者
Kurtulan, O. [1 ]
Turhan, N. [2 ]
Gedikoglu, G. [1 ]
Akyol, A. [1 ]
Sokmensuer, C. [1 ]
机构
[1] Hacettepe Univ, Fac Med, Dept Pathol, Ankara, Turkey
[2] Univ Hlth Sci, Ankara City Hosp, Dept Pathol, Ankara, Turkey
关键词
gastric neuroendocrine tumors; grade; clinicopathologic classification; prognosis; CARCINOID-TUMORS; TYPE-1; EPIDEMIOLOGY; MANAGEMENT; NEOPLASIA;
D O I
10.51821/85.2.8601
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Gastric neuroendocrine tumors [gNETs] are heterogeneous tumors and we are still unable to predict the behavior of these tumors. We aim to define the prognostic parameters of well-differentiated gNETs based on metastatic potential and to evaluate the current classification systems. Patients and methods: We retrospectively retrieved 44 well differentiated gNET cases who underwent radical surgery between 2000-2015 at two tertiary-care centers. Results: Among the 44 well-differentiated gNET patients, 17 (38%) patients had metastatic disease to lymph nodes and/or distant sites, while 27 (62%) were confined to the stomach. Higher risk of metastasis was observed with increasing tumor size, grade, depth of invasion and with type-3 and solitary tumors. 30 (68%) patients had type-1 gNET and 14 (32%) had type-3 gNET. Majority of the type-1 cases (76,6%) were Grade 1 [G1] and type-3 cases (78,5%) were Grade 3 [G3]. Type-1 subgroup had no G3 tumor, and type-3 had no G1. Grade 2 [G2] tumors were more controversial, with metastatic and non-metastatic cases. G2 cases with a >10% Ki67 expression or type-3, had a worse prognosis. Although most of the type-1 gNETs had an indolent course, 6 of 30 (20%) patients had metastatic disease. Metastasizing type-1 gNETs were >10 mm in diameter or extended to/beyond the submucosa. Conclusion: Regarding our results, tumor type, grade, size, focality and depth of invasion are the prognostic parameters for gNETs, based on metastatic potential. Besides these parameters, a two-tiered grading system with a 10% Ki-67 proliferation index cut-off value could be considered for right treatment choice. (Acta gastroenterol. belg., 2022, 85, 339-345).
引用
收藏
页码:339 / 345
页数:7
相关论文
共 44 条
  • [21] Morbidity and Outcomes of Primary Tumor Management in Patients with Widely Metastatic Well-Differentiated Small Bowel Neuroendocrine Tumors
    Nigam, Aradhya
    Li, Janet W. Y.
    Fiasconaro, Megan
    Lin, Sabrina
    Capanu, Marinela
    Kleiman, David A.
    Memeh, Kelvin
    Raj, Nitya
    Reidy-Lagunes, Diane L.
    Untch, Brian R.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (04) : 2337 - 2348
  • [22] Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors
    Massimo Milione
    Patrick Maisonneuve
    Alessio Pellegrinelli
    Sara Pusceddu
    Giovanni Centonze
    Francesca Dominoni
    Cecilia Brambilla
    Manila Rubino
    Antongiulio Faggiano
    Roberto Buzzoni
    Laura Concas
    Luca Giacomelli
    Jorgelina Coppa
    Vincenzo Mazzaferro
    Filippo de Braud
    Endocrine, 2017, 57 : 512 - 517
  • [23] Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic
    Rose, Darya B.
    Nellesen, Dave
    Neary, Maureen P.
    Cai, Beilei
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (04) : 395 - 404
  • [24] A Single Institution's Experience with Surgical Cytoreduction of Stage IV, Well-Differentiated, Small Bowel Neuroendocrine Tumors
    Boudreaux, J. Philip
    Wang, Yi-Zarn
    Diebold, Anne E.
    Frey, Daniel J.
    Anthony, Lowell
    Uhlhorn, Ann Porter
    Ryan, Pamela
    Woltering, Eugene A.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2014, 218 (04) : 837 - 844
  • [25] Silencing of UCHL1 by CpG Promoter Hyper-methylation is Associated with Metastatic Gastroenteropancreatic Well-Differentiated Neuroendocrine (Carcinoid) Tumors
    Kleiman, David A.
    Beninato, Toni
    Sultan, Samuel
    Crowley, Michael J. P.
    Finnerty, Brendan
    Kumar, Ritu
    Panarelli, Nicole C.
    Liu, Yi-Fang
    Lieberman, Michael D.
    Seandel, Marco
    Evans, Todd
    Elemento, Olivier
    Zarnegar, Rasa
    Fahey, Thomas J., III
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S672 - S679
  • [26] CD133 expression in well-differentiated pancreatic neuroendocrine tumors: a potential predictor of progressive clinical courses
    Sakai, Yasuhiro
    Hong, Seung-Mo
    An, Soyeon
    Kim, Joo Young
    Corbeil, Denis
    Karbanova, Jana
    Otani, Kyoko
    Fujikura, Kohei
    Song, Ki-Byung
    Kim, Song Cheol
    Akita, Masayuki
    Nanno, Yoshihide
    Toyama, Hirochika
    Fukumoto, Takumi
    Ku, Yonson
    Hirose, Takanori
    Itoh, Tomoo
    Zen, Yoh
    HUMAN PATHOLOGY, 2017, 61 : 148 - 157
  • [28] Prognostic validity of the American joint committee on cancer eighth edition staging system for well-differentiated pancreatic neuroendocrine tumors
    Wang, Hebin
    Ding, Ding
    Qin, Tingting
    Zhang, Hang
    Liu, Jun
    Zhao, Junfang
    Wu, Chien-Hui
    Javed, Ammar
    Wolfgang, Christopher
    Guo, Shiwei
    Chen, Qingmin
    Zhao, Weihong
    Shi, Wei
    Zhu, Feng
    Guo, Xingjun
    Li, Xu
    Peng, Feng
    He, Ruizhi
    Xu, Simiao
    Jin, Jikuan
    Wu, Yi
    Nuer, Abula
    Edil, Barish
    Tien, Yu-Wen
    Jin, Gang
    Zheng, Lei
    He, Jin
    Liu, Jianhua
    Liu, Yahui
    Wang, Min
    Qin, Renyi
    HPB, 2022, 24 (05) : 681 - 690
  • [29] Evaluation of immunohistochemical expression of novel neuroendocrine marker INSM1 and histological tumor growth pattern in well-differentiated neuroendocrine tumors of the appendix: 15-year single tertiary center experience
    Koyuncuer, Ali
    Canbak, Tolga
    Acar, Aylin
    Sahin, Onur
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2024, 67 (02) : 282 - 288
  • [30] Prognostic value of whole-body PET volumetric parameters extracted from 68Ga-DOTATOC-PETICT in well-differentiated neuroendocrine tumors
    Thuillier, P.
    Liberini, V
    Grimaldi, S.
    Rampado, O.
    Gallo, E.
    De Santi, B.
    Ceci, F.
    Arvat, E.
    Piovesan, A.
    Filippi, R.
    Molinari, F.
    Deandreis, D.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 198 - 198